Display Settings:

Format

Send to:

Choose Destination
See comment in PubMed Commons below
Eur J Hum Genet. 2008 Jan;16(1):14-7. Epub 2007 Oct 24.

Molecular screening for familial hypercholesterolaemia: consequences for life and disability insurance.

Author information

  • 1General Medical Affairs, Dutch Association of Insurers, The Hague, The Netherlands. S.Homsma@verzekeraars.nl

Erratum in

  • Eur J Hum Genet. 2008 Feb;16(2):275.

Abstract

In The Netherlands, cascade screening to identify patients with familial hypercholesterolaemia (FH) has been introduced in 1994; a nationwide screening programme is currently ongoing to detect all - approximately 40 000 - carriers by molecular screening. Active identification by DNA testing has social implications such as difficulties in obtaining life and disability insurance. In The Netherlands, insurance companies are restricted in the use of genetic information of their clients by the Medical Examination Act (1998). Within the scope of this specific law, the Foundation for the Identification of Persons with Inherited Hypercholesterolaemia, the patient support association, representatives of the medical profession as well as insurers designed guidelines for risk assessment of mortality and morbidity of FH carriers. Risk assessment should be based on phenotype, that is, lipoprotein profile and the presence of classical cardiovascular risk, instead of the LDL receptor gene mutation. Applicants with FH should be accepted at normal rates if LDL-c levels are <4.0 mmol/l, in the absence of additional risk factors. After implementation of these guidelines, the number of complaints about insurance contracts has decreased markedly.

PMID:
17957228
[PubMed - indexed for MEDLINE]
Free full text
PubMed Commons home

PubMed Commons

0 comments
How to join PubMed Commons

    Supplemental Content

    Full text links

    Icon for Nature Publishing Group
    Loading ...
    Write to the Help Desk